Billable / Specific Code
ICD-10-CM C76.40 is the diagnosis code for Malignant neoplasm of unspecified upper limb. This code falls under the section "Malignant neoplasms of ill-defined, other secondary and unspecified sites" within Chapter 2 — Neoplasms (C00-D49). It is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. Medical coders and healthcare providers use this code to document and classify diagnoses in electronic health records, insurance claims, and clinical databases.
Always refer to the official ICD-10-CM Tabular List for complete coding guidelines. Ensure documentation supports the specificity of the code selected. When in doubt, consult a certified medical coder or the latest CMS guidelines.
Understanding where C76.40 sits in the ICD-10-CM classification helps ensure proper coding:
Yes, C76.40 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
C76.40 is the ICD-10-CM diagnosis code for "Malignant neoplasm of unspecified upper limb". It is used by healthcare providers to classify and document this condition in medical records and insurance claims.
The parent code of C76.40 is C76.4 ("Malignant neoplasm of upper limb"). C76.40 provides a more specific classification within this category.
C76.40 is located in Section C76-C80 — "Malignant neoplasms of ill-defined, other secondary and unspecified sites" within Chapter 2 of the ICD-10-CM Tabular List.
Use C76.40 when the patients documented diagnosis matches "Malignant neoplasm of unspecified upper limb" and the clinical documentation supports this level of specificity. Always verify with the latest ICD-10-CM guidelines and payer requirements.
The ICD-10-CM code for Malignant neoplasm of unspecified upper limb is C76.40.
Yes, C76.40 can be used as a primary diagnosis code since it is billable and specific.
C76.40 is in Chapter 2 of the ICD-10-CM Tabular List.
Yes, C76.40 is a valid ICD-10-CM code for the 2026 fiscal year, subject to official CMS updates.